New research reveals that people who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who end traditional diet and exercise plans.
Findings released in a prominent health publication shows that while overweight people can lose substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"People using these drugs should be aware of the potential of fast rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of regain means a reversion to original mass within about a year and a half.
Weighing Therapies
The study, which reviewed dozens of studies involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that people who shed pounds through dieting usually have a slower weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Experts propose the mode of action of the drugs is key to understanding the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication means hunger is unsuppressed, making overeating far more likely."
A Lifelong Condition?
The NHS advise the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, due to the high risk of relapse, the treatment should be considered long-term.
This view is echoed by drug manufacturers, who state that the findings "underscore the persistent nature of obesity," similar to managing diseases like hypertension.
Patient Experiences
Users who have discontinued the jabs describe a intense resurgence of appetite.
"It felt as if a trigger that goes on and you're instantly extremely hungry," recalled one woman.
This challenge is exacerbated if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Significant Adoption
Survey data show that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits relies on integrated lifestyle support.
